A previous study has shown a correlation between quantitative cfDNA levels and tumor‐specific KRAS and EGFR mutations in plasma, which triggered us to hypothesize that increasing levels of cfDNA in patients with cancer are primarily of tumor origin 44, 53, 54, 55, 56. The gene discussed is KRAS; the disease is neoplasm.